NCT04182932View on ClinicalTrials.gov

Safety and Immunogenicity of CJ-40010 in Healthy Subjects

PHASE1UnknownINTERVENTIONAL
Enrollment

60

Participants

Timeline

Start Date

December 2, 2019

Primary Completion Date

November 30, 2021

Study Completion Date

December 31, 2021

Conditions
Hand, Foot and Mouth Disease
Interventions
BIOLOGICAL

CJ-40010 EV71 vaccine A dose

Inactivated vaccine against EV71, three doses, 28 days interval

BIOLOGICAL

CJ-40010 EV71 vaccine B dose

Inactivated vaccine against EV71, three doses, 28 days interval

BIOLOGICAL

CJ-40010 CVA16 vaccine C dose

Inactivated vaccine against CVA16, three doses, 28 days interval

BIOLOGICAL

CJ-40010 CVA16 vaccine D dose

Inactivated vaccine against CVA16, three doses, 28 days interval

BIOLOGICAL

CJ-40010 Bivalent vaccine E dose

Inactivated vaccine against EV71/CVA16, three doses, 28 days interval

BIOLOGICAL

CJ-40010 Bivalent vaccine high dose

Inactivated vaccine against EV71/CVA16, three doses, 28 days interval

BIOLOGICAL

Placebo

Placebo, three doses, 28 days interval

Trial Locations (1)

Unknown

RECRUITING

Seoul National University Hospital, Clinical Trial Center, Seoul

Sponsors
All Listed Sponsors
lead

HK inno.N Corporation

INDUSTRY